Form 4: Travere Therapeutics Director Timothy Coughlin Reports Stock Transactions

Director Timothy Coughlin reports acquisition of shares and stock options in Travere Therapeutics under the company's equity incentive plan.

Summary

• On May 8, 2024, Timothy Coughlin, a director of Travere Therapeutics, acquired 6,500 shares of common stock.
• These shares were obtained through an automatic equity grant under the company's 2018 Equity Incentive Plan.
• The price of these shares was $0.
• Coughlin also acquired a stock option to buy 19,500 shares of common stock at an exercise price of $6.82.
• This option vests over a one-year period and expires on May 7, 2034.
• Following these transactions, Coughlin directly owns 19,500 derivative securities and 49,000 common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions reflect a director's continued investment in the company, which is generally viewed favorably. However, it's a routine filing and doesn't contain significant news.

Positives

• The equity grant and stock option acquisition reflect the director's ongoing investment and alignment with the company's long-term success.
• The vesting schedule of the stock option incentivizes continued service and contribution to Travere Therapeutics.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Equity grants to non-employee directors are a common practice in the pharmaceutical industry to align their interests with those of shareholders.
• The vesting period of one year for the stock options is a typical arrangement to incentivize continued service.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the director's holdings and alignment with company performance.

Key Dates